Studies have linked the expression of excision repair cross-complementation group 1 (ERCC1) gene to chemoresistance as well as to poor survival in many types of cancer such as non-small-cell lung cancer, ovarian and gastric tumors (6-9). Here, ERCC1 is linked to gastric neoplasm.